ArticleHaematologica2011
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment.Blood cancer journal · 2015Trial
- Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia.Cureus · 2022Article
- The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.International journal of hematologic oncology · 2022Review
- The two facets of receptor tyrosine kinase in cardiovascular calcification-can tyrosine kinase inhibitors benefit cardiovascular system?Frontiers in cardiovascular medicine · 2022Review
- BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.Microcirculation (New York, N.Y. : 1994) · 2020Article
- From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.Antioxidants & redox signaling · 2019Review
- Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.Leukemia research · 2017Review
- Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative StudyAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions.Oncotarget · 2017Review
- Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors.Contemporary oncology (Poznan, Poland) · 2016Article
- Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.Annals of hematology · 2015Observational
- Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.American journal of cancer research · 2015Article
- A critical history of chromic myeloid leukemia.Mediterranean journal of hematology and infectious diseases · 2014Article
- Treatment recommendations for chronic myeloid leukemia.Mediterranean journal of hematology and infectious diseases · 2014Review
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Blood · 2013Review
- Clinical cardiac safety profile of nilotinib.Haematologica · 2012Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.